Glucose: A vital toxin and potential utility of melatonin in protecting against the diabetic state

Molecular and Cellular Endocrinology

Volumn 349, Issue 2, 2012, Pages 128-137

  Korkmaz, Ahmet ^a,b   Ma, Shuran ^b   Topal, Turgut ^a   Rosales Corral, Sergio ^b   Tan, Dun Xian ^b   Reiter, Russel J ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Diabetes; Hyperglycemia; Insulin resistance; Melatonin

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; MELATONIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; GLUCOSE TRANSPORTER 4; INSULIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; EPIGENETICS; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PINEAL BODY; PREVENTION STUDY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; ADIPOCYTE; ANIMAL; DRUG ANTAGONISM; GLYCOSYLATION; INFLAMMATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ADIPOCYTES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSE TRANSPORTER TYPE 4; GLYCOSYLATION; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MELATONIN; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84862588786     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.10.013     Document Type: Review

References (156)

1. Alonso-Vale M.I., Andreotti S., Peres S.B., Anhe G.F., das Neves Borges-Silva C., Neto J.C., Lima F.B. Melatonin enhances leptin expression by rat adipocytes in the presence of insulin. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E805-E812.
2. Alonso-Vale M.I., Peres S.B., Vernochet C., Farmer S.R., Lima F.B. Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPbeta transcriptional activity. J. Pineal Res. 2009, 47:221-227.
3. Andersson A.K., Sandler S. Melatonin protects against streptozotocin, but not interleukin-1beta-induced damage of rodent pancreatic beta-cells. J. Pineal Res. 2001, 30:157-165.
4. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv. Cardiol. 2008, 45:1-16.
5. 2+ release from INS1 insulinoma cells. J. Pineal Res. 2005, 39:316-323.
6. Baydas G., Canatan H., Turkoglu A. Comparative analysis of the protective effects of melatonin and vitamin E on streptozocin-induced diabetes mellitus. J. Pineal Res. 2002, 32:225-230.
7. Baydas G., Kutlu S., Naziroglu M., Canpolat S., Sandal S., Ozcan M., Kelestimur H. Inhibitory effects of melatonin on neural lipid peroxidation induced by intracerebroventricularly administered homocysteine. J. Pineal Res. 2003, 34:36-39.
8. Baydas G., Reiter R.J., Yasar A., Tuzcu M., Akdemir I., Nedzvetskii V.S. Melatonin reduces glial reactivity in the hippocampus, cortex, and cerebellum of streptozotocin-induced diabetic rats. Free Radic. Biol. Med. 2003, 35:797-804.
9. Baydas G., Tuzcu M., Yasar A., Baydas B. Early changes in glial reactivity and lipid peroxidation in diabetic rat retina: effects of melatonin. Acta Diabetol. 2004, 41:123-128.
10. Becker-André M., Wiesenberg I., Schaeren-Wiemers H., Andre E., Missbach M., Saurat J.H., Carlberg C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J. Biol. Chem. 1994, 269:28531-28534.
11. Benot S., Goberna R., Reiter R.J., Garcia-Maurino S., Osuna C., Guerrero J.M. Physiological levels of melatonin contribute to the antioxidant capacity of human blood. J. Pineal Res. 1999, 27:59-64.
12. Bettahi I., Pozo D., Osuna C., Reiter R.J., Acuna-Astroviejo D., Guerrero J.M. Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J. Pineal Res. 1996, 20:205-210.
13. Bonnefont-Rousselot D., Collin F., Jose D., Gardes-Albert M. Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J. Pineal Res. 2011, 50:328-335.
14. Boutin J.A., Saunier C., Guenin S.P., Berger S., Maulharat N., Gohier A., Delagrange P., Coge F., Ferry G. Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis. Arch. Biochem. Biophys. 2008, 477:12-19.
15. Bubenik G.A. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig. Dis. Sci. 2002, 47:2336-2348.
16. Cam M., Yavuz O., Guven A., Ercan F., Bukan N., Ustundag N. Protective effects of chronic melatonin treatment against renal injury in streptozotocin-induced diabetic rats. J. Pineal Res. 2003, 35:212-220.
17. Carrillo-Vico A., Guerrero J.M., Lardone P.J., Reiter R.J. A review of the multiple actions of melatonin on the immune system. Endocrine 2005, 27:189-200.
18. Cesaratto L., Vascotto C., Calligaris S., Tell G. The importance of redox state in liver damage. Ann. Hepatol. 2004, 3:86-92.
19. Chahbouni M., Escames G., Venegas B., Sevilla B., Garcia J.A., Lopez L.C., Munoz-Hoyos A., Molina-Carballo A., Acuna-Castroviejo D. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J. Pineal Res. 2010, 48:282-289.
20. Champney T.H., Brainard G.C., Richardson B.A., Reiter R.J. Experimentally-induced diabetes reduces nocturnal pineal melatonin content in the Syrain hamster. Comp. Biochem. Physiol. A Comp. Physiol. 1983, 76:199-201.
21. Chuang J.I., Natarajan M., Meltz M., Reiter R.J. Effect of melatonin on NF-B DNA-binding activity in the rat spleen. Cell. Biol. Int. 1996, 20:687-692.
22. Cohen J.D. Overview of physiology, vascular biology, and mechanisms of hypertension. J. Manag. Care Pharm. 2007, 13(5 Suppl.):S6-S8.
23. Colantuoni A., Longoni B., Marchiafava P.L. Retinal photoreceptors of Syrian hamsters undergo oxidative stress during streptozotocin-induced diabetes. Diabetologia 2002, 45:121-124.
24. Conti A., Conconi S., Hertens E., Skwarlo-Sonta K., Markowska M., Maestroni J.M. Evidence for melatonin synthesis in mouse and human bone marrow cells. J. Pineal Res. 2000, 28:193-202.
25. D'Elia J.A., Bayliss G., Roshan B., Maski M., Gleason R.E., Weinrauch L.A. Diabetic microvascular complications: possible targets for improved microvascular outcomes. Int. J. Nephrol. Renovasc. Dis. 2011, 4:1-15.
26. Deng W.G., Tang S.T., Tseng H.P., Wu K.K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006, 108:518-524.
27. Derlacz R.A., Poplawski P., Napierala M., Jagielski A.K., Bryla J. Melatonin-induced modulation of glucose metabolism in primary cultures of rabbit kidney-cortex tubules. J. Pineal Res. 2005, 38:164-169.
28. Ding H., Triggle C.R. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc. Health Risk Manag. 2005, 1:55-71.
29. Dong W.-G. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J. Gastroenterol. 2003, 9:1307-1311.
30. Dubocovich M.L., Markowska M. Functional MT1 and MT2 receptors in mammals. Endocrine 2005, 27:101-110.
31. Espino J., Pariente J.A., Rodriguez A.B. Role of melatonin in diabetes-related metabolic disorders. World J. Diabetes 2011, 15:82-91.
32. Esposito E., Iacono A., Muia C., Crisafulli C., Mattace Raso G., Bramanti P., Meli R., Cuzzocrea S. Signal transduction pathways involved in protective effects of melatonin in C6 glioma cells. J. Pineal Res. 2008, 44:78-87.
33. Esposito E., Mazzon E., Ricarrdi L., Caminiti R., Meli R., Cuzzocrea S. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J. Pineal Res. 2008, 45:166-173.
34. Fischer T.W., Zbytek B., Sayre R.M., Apostolov E.O., Basnakian A.G., Sweatman T.W., Wortsman J., Elsner P., Slominski A. Melatonin increases survival of HaCaT keratinocytes by suppressing UV-induced apoptosis. J. Pineal Res. 2006, 40:18-26.
35. Galano A., Tan D.X., Reiter R.J. Melatonin as a natural ally against oxidative stress: a physiochemical examination. J. Pineal Res. 2011, 51:1-16.
36. Ganguly K., Swanakar S. Induction of matrix metalloproteinase-9 and -3 in nonsteroidal anti-inflammatory drug-induced acute gastric ulcers in mice: regulation by melatonin. J. Pineal Res. 2009, 47:43-55.
37. Garvey W.T., Maianu L., Hancock J.A., Golichowski A.M., Baron A. Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 1992, 41:465-475.
38. Ghosh G., De K., Maity S., Bandyopadhyay D., Bhattacharya S., Reiter R.J., Bandyopadhyay A. Melatonin protects against oxidative damage and restores expression of GLUT-4 gene in the hyperthyroid rat heart. J. Pineal Res. 2007, 42:71-82.
39. Giaccari A., Sorice G., Museogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment nutrition, metabolism and cardiovascular diseases. Nutr. Metab. Cardiovasc. Dis. 2009, 19:365-377.
40. Grankvist K., Marklund S., Sehlin J., Taljedal I.B. Superoxide dismutase, catalase and scavengers of hydroxyl radical protect against the toxic action of alloxan on pancreatic islet cells in vitro. Biochem. J. 1979, 1821:17-25.
41. Gultekin F., Delibas N., Yasar S., Kilinc I. In vivo changes in antioxidant systems and protective role of melatonin and a combination of vitamin C and vitamin E on oxidative damage in erythrocytes induced by chlorpyrifos-ethyl in rats. Arch. Toxicol. 2001, 75:88-96.
42. Hardeland R. Melatonin and its metabolites as anti-nitrosating and anti-nitrating agents. J. Exp. Integr. Med. 2011, 1:67-81.
43. Hardeland R., Tan D.X., Reiter R.J. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J. Pineal Res. 2009, 47:109-126.
44. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
45. Hsu C., Han B., Liu M., Yeh C., Casida J.E. Phosphine-induced oxidative damage in rats: attenuation by melatonin. Free Radic. Biol. Med. 2000, 28:636-642.
46. Huether G. The contribution of extra pineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia 1993, 49:665-670.
47. Jahnke G., Marr M., Myers C., Wilson R., Travlos G., Price C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol. Sci. 1999, 50:271-279.
48. Jan J.E., Freeman R.D., Fast D.K. Melatonin treatment of sleep-wake cycle disorders in children and adolescents. Dev. Med. Child Neurol. 1999, 41:491-500.
49. Jan J.E., Hamilton D., Seward N., Fast D.K., Freeman R.D., Laudon M. Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. J. Pineal Res. 2000, 29:34-38.
50. Jung-Hynes B., Huang W., Reiter R.J., Ahamad W. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J. Pineal Res. 2010, 49:60-68.
51. Jung-Hynes B., Reiter R.J., Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J. Pineal Res. 2010, 48:9-19.
52. Kasradze D., Tavartkiladze A., Kasradze M., Kozadze P. The study of melatonin protective activity on pancreatic β-cells under the condition of alloxan-induced diabetes during aging. Georgian Med. News 2010, 189:56-63.
53. Kiersztan A., Winiarska K., Drozak J., Przedlacka M., Wegrzynowicz M., Fraczyk T., Bryla J. Differential effects of vanadium, tungsten and molybdenum on inhibition of glucose formation in renal tubules and hepatocytes of control and diabetic rabbits: beneficial action of melatonin and N-acetylcysteine. Mol. Cell. Biochem. 2004, 261:9-21.
54. Kilanczyk E., Bryszewska M. The effect of melatonin on antioxidant enzymes in human diabetic skin fibroblasts. Cell Mol. Biol. Lett. 2003, 8:333-336.
55. Kirkland J.L., Tchkonia T., Pirtskhalava T., Han J., Karagiannides I. Adipogenesis and aging: does aging make fat go MAD?. Exp. Gerontol. 2002, 37:757-767.
56. Koppisetti S., Jenigiri B., Terron M.P., Tengattini S., Tamura H., Flores L.J., Tan D.X., Reiter R.J. Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review. Dig. Dis. Sci. 2008, 53:2592-2603.
57. Korkmaz A., Reiter R.J. Epigenetic regulation: a new research area for melatonin?. J. Pineal Res. 2008, 44:41-44.
58. Korkmaz A., Tamura H. Night-shift, risk of chronic disesases and melatonin rhythm. TAF Prev. Med. Bull. 2008, 7:529-534.
59. Korkmaz A., Topal T., Oter S., Tan D.X., Reiter R.J. Hyperglycemia-related pathophysiologic mechanisms and potential beneficial actions of melatonin. Mini Rev. Med. Chem. 2008, 8:1144-1153.
60. Korkmaz A., Sanchez-Barcelo E.J., Tan D.X., Reiter R.J. Role of melatonin in the epigenetic regulation of breast cancer. Breast Cancer Res. Treat. 2009, 115:13-27.
61. Korkmaz A., Tamura H., Manchester L.C., Ogden G.B., Tan D.X., Reiter R.J. Combination of melatonin and a peroxisome proliferator-activated receptor-gamma agonist induces apoptosis in a breast cancer cell line. J. Pineal Res. 2009, 47:115-116.
62. Korkmaz A., Topal T., Tan D.X., Reiter R.J. Role of melatonin in metabolic regulation. Rev. Endocr. Metab. Disord. 2009, 10:261-270.
63. Leibowitz M.D., Ardecky R.J., Boehm M.F., Broderick C.L., Carfagna M.A., Crombie D.L., D'Arrigo J., Etgen G.J., Faul M.M., Grese T.A., Havel H., Hein N.I., Heyman R.A., Jolley D., Klausing K., Liu S., Mais D.E., Mapes C.M., Marschke K.B., Michellys P.Y., Montrose-Rafizadeh C., Ogilvie K.M., Pascual B., Rungta D., Tyhonas J.S., Urcan M.S., Wardlow M., Yumibe N., Reifel-Miller A. Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. Endocrinology 2006, 147:1044-1053.
64. Lewy A.J., Webr T.A., Goudivin F.K., Newsome D.A., Markey S.P. Light suppresses melatonin secretion in humans. Science 1980, 210:1267-1269.
65. Li J.H., Yu J.P., Yu H.G., Xu X.M., Yu L.L., Liu J., Luo H.S. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005, 28:185-193.
66. Li X., Hansen P.A., Xi L., Chandraratna R.A., Burant C.F. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors. J. Biol. Chem. 2005, 280:38317-38327.
67. Longatti P., Perin A., Rizzo V., Comai S., Giusti P., Costa C.V. Ventricular cerebrospinal fluid melatonin concentrations investigated with an endoscopic technique. J. Pineal Res. 2007, 42:113-118.
68. Madonna R., De Caterina R. Cellular and molecular mechanisma of vascular injury in diabetes - part II: cellular mechanisms and therapueutic targets. Vascul. Pharmacol. 2011, 54:75-79.
69. Maldonado M.D., Murillo-Cabezas F., Terron M.P., Flores L.J., Tan D.X., Manchester L.C., Reiter R.J. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J. Pineal Res. 2007, 42:1-11.
70. Manda K., Ueno M., Anzai K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J. Pineal Res. 2007, 42:386-393.
71. Medina R.A., Owen G.I. Glucose transporters: expression, regulation and cancer. Biol. Res. 2002, 35:9-26.
72. Miura T., Suzuki W., Ishihara E., Arai I., Ishida H., Seino Y., Tanigawa K. Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type 2 diabetes. Eur. J. Endocrinol. 2001, 145:785-790.
73. Mohamed A.K., Bierhaus A., Schiekofer S., Tritschler H., Ziegler R., Nawroth P.P. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999, 10:157-167.
74. Mokini Z., Chiarelli F. The molecular basis of diabetic microangiopathy. Pediatr. Endocrinol. Rev. 2006, 4:138-152.
75. Montilla P.L., Vargas J.F., Tunez I.F., Munoz de Agueda M.C., Valdelvira M.E., Cabrera E.S. Oxidative stress in diabetic rats induced by streptozotocin: protective effects of melatonin. J. Pineal Res. 1998, 25:94-100.
76. Montilla P., Cruz A., Padillo F.J., Tunez I., Gascon F., Munoz M.C., Gomez M., Pera C. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J. Pineal Res. 2001, 31:138-144.
77. Mulder H., Nagorny C.L.F., Lyssenko V., Groop L. Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabeblogia 2009, 52:1240-1249.
78. Mustonen A.M., Nieminen P., Hyvarinen H. Preliminary evidence that pharmacologic melatonin treatment decreases rat ghrelin levels. Endocrine 2001, 16:43-46.
79. Natarajan M., Sadeghi K., Reiter R.J., Meltz M. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-B. Biochem. Mol. Biol. Int. 1995, 37:1063-1070.
80. Nduhirabandi F., Du Toit E.F., Blackhurst D., Marais D., Lochner A. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J. Pineal Res. 2011, 50:171-182.
81. Negi G., Komar A., Sharma S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades. J. Pineal Res. 2011, 50:124-131.
82. Newsholme P., Haber E.P., Hirabara S.M., Rebelato E.L., Procopio J., Morgan D., Oliveira-Emilio H.C., Carpinelli A.R., Curi R. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J. Physiol. 2007, 583(Pt. 1):9-24.
83. Norlund J.J., Lerner A.B. The effects of melatonin on skin color and on the release of pituitary hormones. J. Clin. Endocrinol. Metab. 1977, 45:768-774.
84. Okatani Y., Wakatsuki A., Reiter R.J. Melatonin counteracts potentiation by homocysteine of KCl-induced vasoconstriction in human umbilical artery: relation to calcium influx. Biochem. Biophys. Res. Commun. 2001, 280:940-944.
85. Park S.Y., Choi G.H., Choi H.I., Ryu J., Jung C.Y., Lee W. Calorie restriction improves whole-body glucose disposal and insulin resistance in association with the increased adipocyte-specific GLUT4 expression in Otsuka Long-Evans Tokushima fatty rats. Arch. Biochem. Biophys. 2005, 436:276-284.
86. Peschke E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res. 2008, 44:26-40.
87. Peschke E., Frese T., Chankiewitz E., Peschke D., Preiss U., Schneyer U., Spessert R., Muhlbauer E. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J. Pineal Res. 2006, 40:135-143.
88. Peschke E., Stumpf I., Bazwinsky I., Litvak L., Dralle H., Muhlbauer E. Melatonin and type 2 diabetes - a possible link?. J. Pineal Res. 2007, 42:350-358.
89. Peschke E., Muhlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24:829-841.
90. Petersen K.F., Shulman G.I. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am. J. Cardiol. 2002, 90:11G-18G.
91. Petersen K.F., Shulman G.I. Etiology of insulin resistance. Am. J. Med. 2006, 119(5 Suppl. 1):S10-S16.
92. Piconi L., Quagliaro L., Assaloni R., Da Ros R., Maier A., Zuodar G., Ceriello A. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab. Res. Rev. 2006, 22:198-203.
93. Pogan I., Bissonnette P., Parent L., Sauve R. The effects of melatonin on Ca(2+) homeostasis in endothelial cells. J. Pineal Res. 2002, 33:37-47.
94. Prunet-Marcassus B., Desbazeille M., Bros A., Louche K., Delagrange P., Renard P., Casteilla L., Penicaud L. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology 2003, 144:5347-5352.
95. Querta Salva M.A., Hartley S., Barbot F., Alvarez J.C., Lofaso F., Guilleminault C. Circadian rhythms, melatonin and despression. Curr. Pharm. Dis. 2011, 17:1459-1470.
96. Quiroz Y., Ferrebuz A., Romero F., Vaziri N.D., Rodriguez-Iturbe B. Melatonin ameliorates oxidative stress, inflammation, proteinuria and progression of renal damage in rats with renal mass reduction. Am. J. Physiol. Renal Physiol. 2008, 294:F336-F344.
97. Rao V.S., Santos F.A., Silva R.M., Teixiera M.G. Effects of nitric oxide synthase inhibitors and melatonin on the hyperglycemic response to streptozotocin in rats. Vascul. Pharmacol. 2002, 38:127-130.
98. Reiter R.J. Melatonin: the chemical expression of darkness. Mol. Cell Endocrinol. 1991, 79:C153-C158.
99. Reiter R.J. Melatonin: lowering the high price of free radicals. News Physiol. Sci. 2000, 15:246-250.
100. Reiter R.J., Richardson B.A., Johnson L.Y., Ferguson B.N., Dink D.T. Pineal melatonin rhythm: reduction in aging Syrian hamsters. Science 1980, 210:1372-1373.
101. Reiter R.J., Craft C.M., Johnson J.E., King T.S., Richardson B.A., Vaughan G.M., Vaughan M.K. Age-associated reduction in nocturnal pineal melatonin levels in female rats. Endocrinology 1981, 109:1295-1297.
102. Reiter R.J., Tan D.X., Sainz R.M., Mayo J.C. Melatonin: reducing the toxicity and increasing the efficiency of drugs. J. Pharm. Pharmacol. 2002, 54:1299-1321.
103. Reiter R.J., Tan D.X., Maldonado M.D. Melatonin as an antioxidant: physiology versus pharmacology. J. Pineal Res. 2005, 39:215-216.
104. Reiter R.J., Gultekin F., Flores L.J., Terron M.P., Tan D.X. Melatonin: potential utility for improving public health. TAF Prev. Med. Bull. 2006, 5:131-158.
105. Reiter R.J., Tan D.X., Korkmaz A., Erren T.C., Piekarski C., Tamura H., Manchester L.C. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit. Rev. Oncog. 2007, 13:303-328.
106. Reiter R.J., Tan D.X., Jou M.J., Korkmaz A., Manchester L.C., Paredes S.D. Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. Neuro Endocrinol. Lett. 2008, 29:391-398.
107. Reiter R.J., Manchester L.C., Tan D.X. Neurotoxins: free radical mechanisms and melatonin protection. Curr. Neuropharmacol. 2010, 8:194-210.
108. Reiter R.J., Tan D.X., Sanchez-Barcelo E., Mediavilla M.D., Gitto E., Korkmaz A. Circadian mechanisms in the regulation of melatonin synthesis: disruption with light at night and the pathophysiological consequences. J. Exp. Integr. Med. 2011, 1:13-22.
109. Reiter, R.J., Tan, D.X., Kormaz, A., Ma, S., in press. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann. Med. PMID 21668294.
110. Ressmeyer A.R., Mayo J.C., Zelosko V., Sainz R.M., Tan D.X., Poeggeler B., Antolin I., Zsizsik B.K., Reiter R.J., Hardeland R. Antioxidant properties of the melatonin metabolite N-acetyl-5-methoxykynuramine (AMK): scavening of free radicals and prevention of protein destruction. Redox. Rep. 2003, 8:205-213.
111. Reyes-Toso C.F., Linares L.M., Ricci C.R., Aran M., Pinto J.E., Rodriguez R.R., Cardinali D.P. Effect of melatonin on vascular reactivity in pancreatectomized rats. Life Sci. 2004, 74:3085-3092.
112. Reyes-Toso C.F., Linares L.M., Ricci C.R., Obaya-Naredo D., Pinto J.E., Rodriguez R.R., Cardinali D.P. Melatonin restores endothelium-dependent relaxation in aortic rings of pancreatectomized rats. J. Pineal Res. 2005, 39:386-391.
113. Robertson R.P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem. 2004, 279:42351-42354.
114. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad and the glutathione connection. Diabetes 2003, 52:581-587.
115. Rodriguez C., Mayo J.C., Sainz R.M., Antolin I., Herrera F., Martin V., Reiter R.J. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 2004, 36:1-9.
116. Rosales-Corral S., Tan D.X., Reiter R.J., Valdivia-Velazquez M., Martinez-Barboza G., Acosta-Martinez J.P., Ortiz G.G. Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E. J. Pineal Res. 2003, 35:80-84.
117. Sack R.L., Lewy A.J., Erb D.L., Vollmer W.M., Singer C.M. Human melatonin production decreases with age. J. Pineal Res. 1986, 3:379-385.
118. Sasaki M., Jordan P., Joh T., Itoh M., Jenkins M., Pavlick K., Minagar A., Alexander S.J. Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kappaB. BMC Gastroenterol. 2002, 2:9.
119. Sharma R., Ottenhof T., Rzeczkowska P.A., Niles L.P. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. J. Pineal Res. 2008, 45:277-284.
120. Shaw P.F., Kennaway D.J., Seamark R.F. Evidence of high concentrations of melatonin in lateral ventricular cerebrospinal fluid of sheep. J. Pineal Res. 1989, 6:201-208.
121. Skinner D.C., Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology 1999, 140:4399-4405.
122. Smirnov A.N. Nuclear melatonin receptors. Biochemistry (Mosc.) 2001, 66:19-26.
123. Smith U. Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance - is insulin resistance initiated in the adipose tissue?. Int. J. Obes. Relat. Metab. Disord. 2002, 26:897-904.
124. Stankov B., Reiter R.J. Melatonin receptors: current status, facts and hypotheses. Life Sci. 1990, 48:971-982.
125. Stefulj J., Hortner M., Ghosh M., Schauenstein K., Rinner I., Wolfler A., Semmler J., Liebmann P.M. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J. Pineal Res. 2001, 30:243-247.
126. Stehle J.H., Saade A., Rawashdeh O., Ackermann K., Jilg A., Sebesteny T., Maronde E. A survey of the molecular details in the human pineal gland in the light of phylogeny structure, function and chronobiological diseases. J. Pineal Res. 2011, 51:17-43.
127. Sudnikovich E.J., Maksimchik Y.Z., Zabrodskaya S.V., Kubyshin V.L., Lapshina E.A., Bryszewska M., Reiter R.J., Zavodnik I.B. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. Eur. J. Pharmacol. 2007, 569:180-187.
128. Swarnakar S., Paul S., Singh L.P., Reiter R.J. Matrix metalloproteinases in health and disease: regulation by melatonin. J. Pineal Res. 2011, 50:8-20.
129. Tamura E.K., Cecon E., Monteiro A.W., Silva C.L., Markus R.P. Melatonin inhibits LPS-induced NO production in rat endothelial cells. J. Pineal Res. 2009, 46:268-274.
130. Tamura H., Takasaki A., Miwa I., Taniguchi R., Maekawa R., Asada H., Taketani T., Matsuoka A., Yamagata Y., Shimamura K., Morioka H., Ishikawa H., Reiter R.J., Sugino N. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J. Pineal Res. 2008, 44:280-287.
131. Tamura H., Nakamura Y., Korkmaz A., Manchester L.C., Tan D.X., Sugino N., Reiter R.J. Melatonin and the ovary: physiological and pathophysiological implications. Fertil. Steril. 2009, 92:328-343.
132. Tan D.X., Chen L.D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin: a potent, endogenous hydroyl radical scavenger. Endocr. J. 1993, 1:57-60.
133. Tan D.X., Manchester L.C., Reiter R.J., Qi W., Hanes M.A., Farley N.J. High physiological levels of melatonin in the bile of mammals. Life Sci. 1999, 65:2523-2529.
134. Tan D.X., Manchester L.C., Reiter R.J., Qi W., Zhang M., Weintraub S.T., Cabrera J., Sainz R.M., Mayo J.C. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochem. Biophys. Acta 1999, 1472:206-214.
135. Tan D.X., Manchester L.C., Terron M.P., Flores L.J., Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 2007, 42:28-42.
136. Tan D.X., Manchester L.C., Sanchez-Barcelo E., Mediavilla M.D., Reiter R.J. Significance of high levels of endogenous melatonin in mammalian cerebrospinal fluid and in the central nervous system. Curr. Neuropharmacol. 2010, 8:162-167.
137. Tan D.X., Manchester L.C., Fuentes-Broto L., Paredes S.D., Reiter R.J. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes. Rev. 2011, 12:167-188.
138. Tanaka Y., Tran P.O., Harmon J., Robertson R.P. A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity. Proc. Natl. Acad. Sci. USA 2002, 99:12363-12368.
139. Tilg H., Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 2008, 14:222-231.
140. Tomas-Zapico C., Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J. Pineal Res. 2005, 39:99-104.
141. United Kingdom Prospective Diabetes Study (UKPDS), 1995. Relative efficacy of randomly allocated diet; sulphylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310, 83-88.
142. Urata Y., Honma S., Goto S., Todoroki S., Iida T., Cho S., Honma K., Kendo T. Melatonin induces gamma-glutamylcysteine synthetose by activator protein-1 in human vascular endothelial cells. Free Radic. Biol. Med. 1999, 27:838-847.
143. Vaughan G.M., Reiter R.J. Pineal dependence of the Syrian hamster's nocturnal serum melatonin surge. J. Pineal Res. 1986, 3:9-14.
144. Vaughan G.M., Pelham R.W., Pang S.F., Laughlin L.L., Wilson K.M., Sandock K.L., Vaughan M.K., Koslow S.H., Reiter R.J. Nocturnal elevation of plasma melatonin in urinary 5-hydroxyindole acetic acid in young men: attempts at modification by brief changes in environmental lighting and sleep and autonomic drugs. J. Clin. Endocrinol. Metab. 1976, 42:752-764.
145. Venegas, C., Garcia, J.A., Escames, G., Ortiz, F., Lopez, A., Doerrier, C., Garcia-Corzo, L., Lopez, L.C., Reiter, R.J., Acuna-Castroviejo, D., in press. Extra pineal melatonin: analysis of its subcellular distribution and daily fluctuations. J. Pineal Res. doi:10.1111/j.1600-079x.2011.00892.
146. Wahab M.H., Akoul E.S., Abdel-Aziz A.A. Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice. Tumori 2000, 86:157-162.
147. Warman, G.R., Painley, M.D., Bolton, C., Cheeseman, J.F., Fernando, A.T. 3rd, Arendt, J., Wirz-Justice, A., 2011. Circadian-related sleep disorders and sleep medication in a New Zealand blind population: an observational prevalence survey. PLoS One:e22073.
148. Wetter T.J., Gazdag A.C., Dean D.J., Cartee G.D. Effect of calorie restriction on in vivo glucose metabolism by individual tissues in rats. Am. J. Physiol. 1999, 276(4 Pt. 1):E728-E738.
149. Wilson P.W., Kannel W.B. Obesity, diabetes and risk of cardiovascular disease in the elderly. Am. J. Geriatr. Cardiol. 2002, 11:119-123.
150. Winiarska K., Fraczyk T., Malinska D., Drozak J., Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J. Pineal Res. 2006, 40:168-176.
151. Wolden-Hanson T., Mitton D.R., McCants R.L., Yellon S.M., Wilkinson C.W., Matsumoto A.M., Rasmussen D.D. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000, 141:487-497.
152. Wood I.S., Trayburn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br. J. Nutr. 2003, 89:3-9.
153. Wu U.I., Mai F.D., Sheu J.N., Chen L.Y., Liu Y.T., Huang H.C., Chang H.M. Melatonin inhibits microglial activation, reduces pro-inflammatory cytokine levels, and rescues hippocampal neurons of adult rats from acute klebsiella pneumoniae meningitis. J. Pineal Res. 2011, 50:159-170.
154. Yavuz O., Cam M., Bukan N., Guven A., Silan F. Protective effect of melatonin on beta-cell damage in streptozotocin-induced diabetes in rats. Acta Histochem. 2003, 105:261-266.
155. Zanquetta M.M., Seraphim P.M., Sumida D.H., Cipolla-Neto J., Machado U.F. Calorie restriction reduces pinealectomy-induced insulin resistance by improving GLUT4 gene expression and its translocation to the plasma membrane. J. Pineal Res. 2003, 35:141-148.
156. Zhang L. Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARγ expression and enhancing Runx2 expression. J. Pineal Res. 2010, 49:364-372.